CN114945388B - 用于成像和治疗的纤维蛋白结合化合物 - Google Patents

用于成像和治疗的纤维蛋白结合化合物 Download PDF

Info

Publication number
CN114945388B
CN114945388B CN202080089490.0A CN202080089490A CN114945388B CN 114945388 B CN114945388 B CN 114945388B CN 202080089490 A CN202080089490 A CN 202080089490A CN 114945388 B CN114945388 B CN 114945388B
Authority
CN
China
Prior art keywords
compound
fibrin
formula
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080089490.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114945388A (zh
Inventor
P·卡拉文
T·J·麦克默瑞
R·J·鲁毕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rumina Pharmaceutical Co Ltd
Original Assignee
Collagen Medical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collagen Medical LLC filed Critical Collagen Medical LLC
Publication of CN114945388A publication Critical patent/CN114945388A/zh
Application granted granted Critical
Publication of CN114945388B publication Critical patent/CN114945388B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080089490.0A 2019-10-23 2020-10-23 用于成像和治疗的纤维蛋白结合化合物 Active CN114945388B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962924997P 2019-10-23 2019-10-23
US62/924,997 2019-10-23
PCT/US2020/057198 WO2021081430A1 (en) 2019-10-23 2020-10-23 Fibrin-binding compounds for imaging and treatment

Publications (2)

Publication Number Publication Date
CN114945388A CN114945388A (zh) 2022-08-26
CN114945388B true CN114945388B (zh) 2025-03-18

Family

ID=75620290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080089490.0A Active CN114945388B (zh) 2019-10-23 2020-10-23 用于成像和治疗的纤维蛋白结合化合物

Country Status (6)

Country Link
US (1) US20240115744A1 (https=)
EP (1) EP4048324A4 (https=)
JP (1) JP2022554186A (https=)
KR (1) KR20220104703A (https=)
CN (1) CN114945388B (https=)
WO (1) WO2021081430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202313965D0 (en) * 2023-09-13 2023-10-25 Univ Oxford Innovation Ltd Radiopharmaceutical

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795015A (zh) * 2003-05-23 2006-06-28 埃匹克斯医药品股份有限公司 螯合配位体和造影剂的光学纯和光学富集异构体
CN102014956A (zh) * 2007-08-17 2011-04-13 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI240632B (en) * 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
WO2007047608A2 (en) * 2005-10-14 2007-04-26 Epix Pharmaceuticals, Inc. Fibrin targeted therapeutics
CN101558081B (zh) * 2006-12-11 2014-08-20 伯拉考成像股份公司 用于诊断和治疗应用的纤维蛋白结合肽缀合体
WO2015038968A1 (en) * 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
US20190216956A1 (en) * 2016-07-27 2019-07-18 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
US20190247520A1 (en) * 2018-01-24 2019-08-15 Carl A. Morris Non-invasive detection of disease progression and therapeutic efficacy for muscular dystrophies and diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795015A (zh) * 2003-05-23 2006-06-28 埃匹克斯医药品股份有限公司 螯合配位体和造影剂的光学纯和光学富集异构体
CN102014956A (zh) * 2007-08-17 2011-04-13 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法

Also Published As

Publication number Publication date
CN114945388A (zh) 2022-08-26
EP4048324A1 (en) 2022-08-31
WO2021081430A1 (en) 2021-04-29
EP4048324A4 (en) 2024-05-15
US20240115744A1 (en) 2024-04-11
KR20220104703A (ko) 2022-07-26
JP2022554186A (ja) 2022-12-28

Similar Documents

Publication Publication Date Title
JP6786731B2 (ja) 二重標的イメージング用分子プローブ及びその調製方法と応用
CN101558081B (zh) 用于诊断和治疗应用的纤维蛋白结合肽缀合体
CA2452923C (en) Peptide-based compounds for targeting integrin receptors
US8628750B2 (en) Cancer imaging and treatment
BR112017008575B1 (pt) Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica
KR20190039153A (ko) 악성 종양 표적 펩티드
CN101537190A (zh) 肽基化合物
JP2024123022A (ja) ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
WO2019092242A1 (en) A double-labeled probe for molecular imaging and use thereof
CN102076214A (zh) 释放胃泌素的肽化合物
WO2016025322A1 (en) Design and development of neurokinin-1 receptor-binding agent delivery conjugates
WO2025060375A1 (zh) 丹磺酰胺修饰的psma靶向化合物及其制备方法和应用
CN114945388B (zh) 用于成像和治疗的纤维蛋白结合化合物
JP7736315B2 (ja) イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト
HK40078955A (en) Fibrin-binding compounds for imaging and treatment
KR20070029200A (ko) 펩티드계 화합물
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
RU2505316C2 (ru) Способ визуализации
Dannoon et al. In vitro structure–activity relationship of Re-cyclized octreotide analogues
KR101551232B1 (ko) Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
WO2010121133A2 (en) Multimodal imaging of fibrin
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
TW202535356A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途
WO2024046469A1 (zh) 环肽及其制备方法、包括其的复合物、及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078955

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251202

Address after: Delaware, USA

Patentee after: Rumina Pharmaceutical Co., Ltd.

Country or region after: U.S.A.

Address before: Massachusetts, USA

Patentee before: Collagen Medical LLC

Country or region before: U.S.A.